Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric F Morand

Showing results (51-60 of 226) with videos related to

Pageof 23
Sort By:
Lupus Science & Medicine|December 8, 2017
Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us?Daniel Boulos, Rachel L Koelmeyer, Eric F Morand, et al.
Annals of the Rheumatic Diseases|October 31, 2018
Response to: 'Comment on: 'Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hocanalysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by IsenbergEric F Morand, Teodora Trasieva, Anna Berglind, et al.
BMJ (Clinical Research Ed.)|October 26, 2023
Advances in the management of systemic lupus erythematosusEric F Morand, Ruth Fernandez-Ruiz, Ashira Blazer, et al.
Rheumatology (Oxford, England)|October 19, 2021
Measurement of specific organ domains in lupus randomized controlled trials: a scoping reviewKathryn Connelly, Jeevan Vettivel, Vera Golder, et al.
Arthritis and Rheumatism|October 12, 2004
Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: up-regulation by interleukin-1beta and glucocorticoidsMyew-Ling Toh, Yuan Yang, Michelle Leech, et al.
Arthritis Research & Therapy|August 24, 2013
Clinical associations of serum interleukin-17 in systemic lupus erythematosusFabien B Vincent, Melissa Northcott, Alberta Hoi, et al.
Annals of the Rheumatic Diseases|February 9, 2018
Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: <i>post-hoc</i> analysis of the Phase IIb MUSE trial of anifrolumabEric F Morand, Teodora Trasieva, Anna Berglind, et al.
The Journal of Rheumatology|June 2, 2004
Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factorLeilani L Santos, Derek Lacey, Yuanhang Yang, et al.
Annals of the Rheumatic Diseases|January 23, 2023
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosusEric F Morand, Gabriel Abreu, Richard A Furie, et al.
Internal Medicine Journal|November 11, 2024
Anti-MDA5 positivity: describing the frequency and spectrum of clinically evident MDA5 diseaseJanelle See, Jessica L Fairley, Ai L Yeo, et al.
Pageof 23

Showing results (51-60 of 226) with videos related to

Sort By:
Pageof 23
Lupus Science & Medicine|December 8, 2017
Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us?Daniel Boulos, Rachel L Koelmeyer, Eric F Morand, et al.
Annals of the Rheumatic Diseases|October 31, 2018
Response to: 'Comment on: 'Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hocanalysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by IsenbergEric F Morand, Teodora Trasieva, Anna Berglind, et al.
BMJ (Clinical Research Ed.)|October 26, 2023
Advances in the management of systemic lupus erythematosusEric F Morand, Ruth Fernandez-Ruiz, Ashira Blazer, et al.
Rheumatology (Oxford, England)|October 19, 2021
Measurement of specific organ domains in lupus randomized controlled trials: a scoping reviewKathryn Connelly, Jeevan Vettivel, Vera Golder, et al.
Arthritis and Rheumatism|October 12, 2004
Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: up-regulation by interleukin-1beta and glucocorticoidsMyew-Ling Toh, Yuan Yang, Michelle Leech, et al.
Arthritis Research & Therapy|August 24, 2013
Clinical associations of serum interleukin-17 in systemic lupus erythematosusFabien B Vincent, Melissa Northcott, Alberta Hoi, et al.
Annals of the Rheumatic Diseases|February 9, 2018
Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: <i>post-hoc</i> analysis of the Phase IIb MUSE trial of anifrolumabEric F Morand, Teodora Trasieva, Anna Berglind, et al.
The Journal of Rheumatology|June 2, 2004
Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factorLeilani L Santos, Derek Lacey, Yuanhang Yang, et al.
Annals of the Rheumatic Diseases|January 23, 2023
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosusEric F Morand, Gabriel Abreu, Richard A Furie, et al.
Internal Medicine Journal|November 11, 2024
Anti-MDA5 positivity: describing the frequency and spectrum of clinically evident MDA5 diseaseJanelle See, Jessica L Fairley, Ai L Yeo, et al.
Pageof 23